House Passes Bill to Extend ALS Research Funding

The legislation provides ongoing funding for ALS research and clinical trial access to support patients through 2031.

Updated on Oct. 29, 2026 in Alzheimer’s

House Passes Bill to Extend ALS Research Funding

Live Poll

Should the federal government prioritize long-term funding for research into fatal diseases?

The U.S. House of Representatives has passed the Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026, which now heads to President Donald Trump. This legislation extends federal funding for ALS research programs through 2031 to support patients facing the 100% fatal neurodegenerative disease.

Why it matters

Extending this funding ensures that pathways for clinical trial access and research grants continue for individuals living with ALS. Because the disease currently lacks a cure, these sustained federal investments are critical for ongoing efforts to find new treatments.

The legislation serves as a reauthorization of existing programs established in 2021, supported by a bipartisan coalition of over 100 co-sponsors. The efficacy of these research grants and access pathways remains under ongoing federal oversight.

The players

Donald Trump

The current President of the United States who holds the authority to sign or veto the legislation.

Food and Drug Administration

The federal agency tasked with creating a new action plan for rare neurodegenerative diseases under the bill.

National Institutes of Health

The government institution that partners with the FDA to conduct medical research and manage clinical trial access.

The details

The bill mandates that the FDA develop an action plan for rare neurodegenerative diseases within 18 months, with a progress report due in five years. By providing structured pathways for clinical trial participation, the act aims to accelerate the development of potential therapies for those with ALS. These programs connect government research grants with partnerships between the FDA and the National Institutes of Health.

1939 marks the year Lou Gehrig was diagnosed with ALS.
2021 was the year the original ACT for ALS programs began.
Nov. 6, 2026, is the deadline for President Donald Trump to act on the bill.
Nov. 7, 2026, is when the bill becomes law if no action is taken.
2031 is the year extended funding for these initiatives expires.

Health Landscape

This legislation builds upon the framework established by the 2021 Accelerating Access to Critical Therapies for ALS Act. It ensures continuity in a specialized research landscape that has historically struggled to bridge the gap between initial clinical investigation and treatment availability.

For patients and families, this legislation reinforces the importance of monitoring clinical trial registries for new research opportunities. It is worth discussing with your neurologist whether current or future clinical trial programs might align with your specific care needs.

The takeaway

The reauthorization of this act provides a stable foundation for the future of neurodegenerative disease research in the United States. Patients should stay informed by tracking updates from their physician regarding new clinical trial eligibility and federal research developments.